{{Drugbox
| IUPAC_name = 2-fluoro-5-hydroxy-L-tyrosine
| image = fluorodopa.png

<!--Clinical data-->
| tradename =  
| pregnancy_AU =
| pregnancy_US = 
| pregnancy_category =  
| legal_AU =
| legal_CA =
| legal_UK =
| legal_US = 
| legal_status =  
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number_Ref =
| CAS_number = 75290-51-6
| ATC_prefix = 
| ATC_suffix = 
| ATC_supplemental = 
| PubChem = 
| DrugBank_Ref =
| DrugBank =  
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 6WIZ27OUZ9
| ChEMBL_Ref = 
| ChEMBL = 
| ChemSpiderID      = 96897

<!--Chemical data-->
| C=9 | H=10 | F=1 | N=1 | O=4 
| molecular_weight = 215.18 g/mol
| synonyms = 6-fluoro-L-DOPA<br>FDOPA
| smiles            = C1=C(C(=CC(=C1O)O)F)C[C@@H](C(=O)O)N
| StdInChI          = 1S/C9H10FNO4/c10-5-3-8(13)7(12)2-4(5)1-6(11)9(14)15/h2-3,6,12-13H,1,11H2,(H,14,15)/t6-/m0/s1
| StdInChIKey       = PAXWQORCRCBOCU-LURJTMIESA-N
}}
'''Fluorodopa''', also known as '''FDOPA''', is a fluorinated form of [[L-DOPA]] primarily synthesized as its [[fluorine-18]] [[isotopologue]] for use as a [[radiotracer]] in [[positron emission tomography]] (PET).<ref name="Deng_2002">{{cite journal |vauthors=-Deng WP, Wong KA, Kirk KL | title = Convenient syntheses of 2-, 5- and 6-fluoro- and 2,6-difluoro-L-DOPA | journal = Tetrahedron: Asymmetry | volume =  13 | issue = 11 | pages = 1135â€“1140 | year = 2002 | month = | pmid = | doi = 10.1016/S0957-4166(02)00321-X}}</ref>
Fluorodopa PET scanning is a valid method for assessing the functional state of the nigrostriatal dopaminergic pathway. It is particularly useful for studies requiring repeated measures such as examinations of the course of a disease and the effect of treatment

==References==
{{reflist}}

[[Category:Catecholamines]]